Literature DB >> 32555427

Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.

You Lu1, Jianxin Xue2, Tao Deng3, Xiaojuan Zhou2, Kun Yu3, Lei Deng4, Meijuan Huang2, Xin Yi5, Maozhi Liang6, Yu Wang7, Haige Shen7, Ruizhan Tong2, Wenbo Wang8, Li Li2, Jin Song5, Jing Li5, Xiaoxing Su9, Zhenyu Ding2, Youling Gong2, Jiang Zhu2, Yongsheng Wang2,6, Bingwen Zou2, Yan Zhang2, Yanying Li2, Lin Zhou2, Yongmei Liu2, Min Yu2, Yuqi Wang5, Xuanwei Zhang2, Limei Yin2, Xuefeng Xia5, Yong Zeng3, Qiao Zhou10, Binwu Ying11, Chong Chen12, Yuquan Wei12, Weimin Li13, Tony Mok14.   

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Entities:  

Year:  2020        PMID: 32555427     DOI: 10.1038/s41591-020-0973-6

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  2 in total

Review 1.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 2.  Application of CRISPR/Cas9 in Alzheimer's Disease.

Authors:  Likui Lu; Xi Yu; Yongle Cai; Miao Sun; Hao Yang
Journal:  Front Neurosci       Date:  2021-12-21       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.